<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967173</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 006</org_study_id>
    <secondary_id>1U10HL098115</secondary_id>
    <nct_id>NCT01967173</nct_id>
  </id_info>
  <brief_title>Best African American Response to Asthma Drugs</brief_title>
  <acronym>BARD</acronym>
  <official_title>Best African American Response to Asthma Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the best asthma treatment to add for Blacks who have
      asthma that is not well controlled on a low dose of inhaled steroid. This study will also try
      to find out if Black adults and children differ in how they respond to the medications used
      in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BARD is a 66 week prospective, randomized, double-blind, crossover trial in Blacks
      (individuals who self-report Black ancestry) who have inadequately controlled asthma while
      taking low-dose inhaled corticosteroids (ICS). BARD will examine the efficacy of increasing
      the dose of ICS with or without the addition of a long-acting beta agonist (LABA) to
      determine whether individual patients respond better to one treatment than another and, if
      so, whether the responses are different for children and adults or if they are related to
      genetic ancestry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome is a Composite Measure That Uses Exacerbations, Asthma Control Days During the Last 12 of 14 Weeks of a Treatment Regimen, and Percent Predicted FEV1 at the End of a Treatment Regimen.</measure>
    <time_frame>The last 12 weeks of each 14-week treatment period</time_frame>
    <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of exacerbations. If one treatment results in fewer exacerbations than another, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by exacerbations, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">574</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent Diskus® 100 mcg</intervention_name>
    <description>Flovent is an ICS</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent Diskus® 250 mcg</intervention_name>
    <description>Flovent is an ICS</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent Diskus® 500 mcg</intervention_name>
    <description>Flovent is an ICS</description>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advair Diskus® 100/50 mcg</intervention_name>
    <description>Advair is an ICS/LABA combination</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advair Diskus® 250/50 mcg</intervention_name>
    <description>Advair is an ICS/LABA combination</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individuals who self-report Black ancestry (with at least 1 Black grandparent).

          2. Able to perform reproducible spirometry according to ATS criteria.

          3. Clinical history consistent with asthma.

          4. Baseline FEV1≥40% of predicted and/or post-bronchodilator FEV1≥40% of predicted.

          5. Asthma confirmed either by: (1) Beta-agonist reversibility to 4 puffs albuterol ≥ 12%
             OR (2) PC20FEV1 ≤ 16 mg/ml OR (3) an absolute relative change in %predicted FEV1 of ≥
             12% over two measurements documented by repeat spirogram over the previous year

          6. Either: A) inadequately controlled on low-, medium- or high-dose ICS monotherapy, or
             low- or medium-dose ICS/LABA, or B) well-controlled on medium- or high-dose ICS
             monotherapy, or low-, medium- or high-dose ICS/LABA. Inadequate asthma control will be
             defined as an ACT/c-ACT score &lt;20; well-controlled asthma will be defined as an
             ACT/c-ACT score ≥20.

          7. Stable asthma controller therapy dose (ICS or ICS/LABA) for the 2 weeks prior to
             enrollment.

          8. Non-smoker (total lifetime smoking history &lt; 5 pack-years if &lt;18, or &lt;10 pack-years if
             ≥18 years of age; no smoking for at least 1 year).

          9. For participants ≥18 years of age: Ability to provide informed consent. For
             participants under 18 years of age: Ability to provide verbal or written assent and
             ability of parent to provide informed consent.

        Exclusion Criteria:

          1. Medical contraindication to LABA or history of adverse reactions to ICS or LABA
             preparations or any of their ingredients.

          2. Current or prior use of medications known to significantly interact with
             corticosteroid disposition within the two-week period preceding enrollment.

          3. Unwilling to provide a blood sample for DNA extraction and genetic analysis.

          4. Major medical problems prohibiting study participation, i.e. presence of chronic or
             active lung disease other than asthma or history of unstable significant medical
             illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's
             disease, Addison's disease, hepatic disease, or concurrent medical problems that could
             require oral corticosteroids during the study or that would place the participant at
             increased risk.

          5. Systemic corticosteroid treatment for any condition within 4 weeks of enrollment or
             more than five courses of systemic corticosteroids in the past year.

          6. History of a life-threatening asthma exacerbation requiring intubation, mechanical
             ventilation, or resulting in a hypoxic seizure within the last 2 years.

          7. History of a respiratory tract infection within 4 weeks of enrollment.

          8. If a female of child-bearing potential, failure to practice abstinence or use an
             acceptable birth control method.

          9. Pregnancy or lactation or planning to get pregnant during the course of the trial.

         10. Receiving hyposensitization therapy other than an established maintenance regimen
             defined as a continuous regimen for ≥ 3 months prior to enrollment.

         11. Participation in an intervention trial or use of investigative drugs in the past 30
             days or plans to enroll in such a trial during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Busse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Urban Population Health</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://asthmanetresearch.org/</url>
    <description>AsthmaNet</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <results_first_submitted>September 10, 2018</results_first_submitted>
  <results_first_submitted_qc>October 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2018</results_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Principal Investigator, AsthmaNet Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Salmeterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01967173/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Crossover Sequence 1</title>
          <description>Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="P2">
          <title>Crossover Sequence 2</title>
          <description>Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="P3">
          <title>Crossover Sequence 3</title>
          <description>Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="P4">
          <title>Crossover Sequence 4</title>
          <description>Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="P5">
          <title>Crossover Sequence 5</title>
          <description>Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="P6">
          <title>Crossover Sequence 6</title>
          <description>Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="P7">
          <title>Crossover Sequence 7</title>
          <description>Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="P8">
          <title>Crossover Sequence 8</title>
          <description>Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="73"/>
                <participants group_id="P6" count="72"/>
                <participants group_id="P7" count="75"/>
                <participants group_id="P8" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1st Period</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="62"/>
                <participants group_id="P7" count="67"/>
                <participants group_id="P8" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2nd Period</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="62"/>
                <participants group_id="P5" count="63"/>
                <participants group_id="P6" count="57"/>
                <participants group_id="P7" count="63"/>
                <participants group_id="P8" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 3rd Period</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="56"/>
                <participants group_id="P7" count="59"/>
                <participants group_id="P8" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 4th Period</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="49"/>
                <participants group_id="P7" count="57"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="49"/>
                <participants group_id="P7" count="57"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Crossover Sequence 1</title>
          <description>Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B2">
          <title>Crossover Sequence 2</title>
          <description>Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B3">
          <title>Crossover Sequence 3</title>
          <description>Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B4">
          <title>Crossover Sequence 4</title>
          <description>Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
Flovent Diskus® 100 mcg: Flovent is an ICS
Flovent Diskus® 250 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B5">
          <title>Crossover Sequence 5</title>
          <description>Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B6">
          <title>Crossover Sequence 6</title>
          <description>Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B7">
          <title>Crossover Sequence 7</title>
          <description>Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B8">
          <title>Crossover Sequence 8</title>
          <description>Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
Flovent Diskus® 250 mcg: Flovent is an ICS
Flovent Diskus® 500 mcg: Flovent is an ICS
Advair Diskus® 100/50 mcg: Advair is an ICS/LABA combination
Advair Diskus® 250/50 mcg: Advair is an ICS/LABA combination</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="73"/>
            <count group_id="B6" value="72"/>
            <count group_id="B7" value="75"/>
            <count group_id="B8" value="74"/>
            <count group_id="B9" value="574"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="2.0"/>
                    <measurement group_id="B2" value="8.5" spread="1.7"/>
                    <measurement group_id="B3" value="8.4" spread="1.9"/>
                    <measurement group_id="B4" value="8.4" spread="1.8"/>
                    <measurement group_id="B5" value="38.5" spread="16.5"/>
                    <measurement group_id="B6" value="38.5" spread="15.9"/>
                    <measurement group_id="B7" value="39.3" spread="16.0"/>
                    <measurement group_id="B8" value="35.6" spread="16.0"/>
                    <measurement group_id="B9" value="23.2" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="47"/>
                    <measurement group_id="B8" value="52"/>
                    <measurement group_id="B9" value="309"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="70"/>
                    <measurement group_id="B7" value="73"/>
                    <measurement group_id="B8" value="71"/>
                    <measurement group_id="B9" value="541"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="71"/>
                    <measurement group_id="B7" value="74"/>
                    <measurement group_id="B8" value="73"/>
                    <measurement group_id="B9" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="72"/>
                    <measurement group_id="B7" value="75"/>
                    <measurement group_id="B8" value="74"/>
                    <measurement group_id="B9" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume at one second (FEV1) Percent of Predicted</title>
          <description>FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.1" spread="15.4"/>
                    <measurement group_id="B2" value="92.6" spread="17.9"/>
                    <measurement group_id="B3" value="95" spread="13.6"/>
                    <measurement group_id="B4" value="96.2" spread="19.1"/>
                    <measurement group_id="B5" value="83.8" spread="19.1"/>
                    <measurement group_id="B6" value="82.9" spread="15.5"/>
                    <measurement group_id="B7" value="83.7" spread="17.3"/>
                    <measurement group_id="B8" value="83.4" spread="18"/>
                    <measurement group_id="B9" value="89.3" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Control Test</title>
          <description>Asthma Control Test: The score is calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled.</description>
          <population>Asthma Control Test is not validated for use in children</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="73"/>
                    <count group_id="B6" value="72"/>
                    <count group_id="B7" value="75"/>
                    <count group_id="B8" value="74"/>
                    <count group_id="B9" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="18.9" spread="3.8"/>
                    <measurement group_id="B6" value="18.6" spread="3.9"/>
                    <measurement group_id="B7" value="19.2" spread="3.7"/>
                    <measurement group_id="B8" value="18.8" spread="3.8"/>
                    <measurement group_id="B9" value="18.9" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Childhood Asthma Control Test</title>
          <description>Childhood Asthma Control Test is for children 4-11 years of age: The score is calculated as the sum total of a 7-item questionnaire. Four items ranges from 0 (poor control) to 3 (good control) and three items ranges from 0 (poor control) to 5 (good control) so so that the range of the total score is 0 to 27. Scores below 20 indicate that asthma is not well controlled.</description>
          <population>Childhood Asthma Control Test is not validated for use in adults</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="71"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.5" spread="3.7"/>
                    <measurement group_id="B2" value="21.2" spread="3.6"/>
                    <measurement group_id="B3" value="20.7" spread="4.1"/>
                    <measurement group_id="B4" value="22.1" spread="3.6"/>
                    <measurement group_id="B9" value="21.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome is a Composite Measure That Uses Exacerbations, Asthma Control Days During the Last 12 of 14 Weeks of a Treatment Regimen, and Percent Predicted FEV1 at the End of a Treatment Regimen.</title>
        <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of exacerbations. If one treatment results in fewer exacerbations than another, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by exacerbations, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
        <time_frame>The last 12 weeks of each 14-week treatment period</time_frame>
        <population>Not all treatments were used in all participants. Flovent 500 was not used in children and Flovent 100 was not used in adolescents and adults</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents and Adults</title>
            <description>All study participant age 12 years or greater</description>
          </group>
          <group group_id="O2">
            <title>Children</title>
            <description>All study participants under age 12 years</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome is a Composite Measure That Uses Exacerbations, Asthma Control Days During the Last 12 of 14 Weeks of a Treatment Regimen, and Percent Predicted FEV1 at the End of a Treatment Regimen.</title>
          <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of exacerbations. If one treatment results in fewer exacerbations than another, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by exacerbations, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
          <population>Not all treatments were used in all participants. Flovent 500 was not used in children and Flovent 100 was not used in adolescents and adults</population>
          <units>probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Advair 100/50 superior to Flovent 250</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".49"/>
                    <measurement group_id="O2" value=".46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 100/50 inferior to Flovent 250</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".28"/>
                    <measurement group_id="O2" value=".46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 100/50 superior to Flovent 500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 100/50 inferior to Flovent 500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 100/50 superior to Advair 250/50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".42"/>
                    <measurement group_id="O2" value=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 100/50 inferior to Advair 250/50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36"/>
                    <measurement group_id="O2" value=".49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 100/50 superior to Flovent 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value=".53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 100/50 inferior to Flovent 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value=".41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 250/50 superior to Flovent 250</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".46"/>
                    <measurement group_id="O2" value=".43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 250/50 inferior to Flovent 250</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".33"/>
                    <measurement group_id="O2" value=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 250/50 superior to Flovent 500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advair 250/50 inferior to Flovent 500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flovent 500 superior to Flovent 250</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flovent 500 inferior to Flovent 250</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flovent 250 superior to Flovent 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value=".51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flovent 250 inferior to Flovent 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value=".37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 100/50 compared to Fluticasone 250 is equal to the inferiority of Advair 100/50 compared to Fluticasone 250</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 100/50 compared to Fluticasone 250 is equal to the inferiority of Advair 100/50 compared to Fluticasone 250</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 100/50 compared to Fluticasone 500 is equal to the inferiority of Advair 100/50 compared to Fluticasone 500</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 100/50 compared to Advair 250/50 is equal to the inferiority of Advair 100/50 compared to Advair 250/50</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 100/50 compared to Advair 250/50 is equal to the inferiority of Advair 100/50 compared to Advair 250/50</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 250/50 compared to Fluticasone 500 is equal to the inferiority of Advair 250/50 compared to Fluticasone 500</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 250/50 compared to Fluticasone 250 is equal to the inferiority of Advair 250/50 compared to Fluticasone 250</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 250/50 compared to Fluticasone 250 is equal to the inferiority of Advair 250/50 compared to Fluticasone 250</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Fluticasone 500 compared to Fluticasone 250 is equal to the inferiority of Fluticasone 500 compared to Fluticasone 250</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Advair 100/50 compared to Fluticasone 100 is equal to the inferiority of Advair 100/50 compared to Fluticasone 100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of the null hypothesis that the superiority of Fluticasone 250 compared to Fluticasone 100 is equal to the inferiority of Fluticasone 250 compared to Fluticasone 100</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each participant was followed over the course of four 14-week treatment periods for a total of 56 weeks. The adverse events recorded below are reported at the treatment period level and represent 14 weeks of &quot;at risk&quot; exposure time.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flovent 250 in Pediatric Group</title>
          <description>Flovent 250 in participants under 12 years</description>
        </group>
        <group group_id="E2">
          <title>Advair 250/50 in Pediatric Group</title>
          <description>Advair 250/50 in participants under 12 years</description>
        </group>
        <group group_id="E3">
          <title>Flovent 100 in Pediatric Group</title>
          <description>Flovent 100 in participants under 12 years</description>
        </group>
        <group group_id="E4">
          <title>Advair 100/50 in Pediatric Group</title>
          <description>Advair 100/50 in participants under 12 years</description>
        </group>
        <group group_id="E5">
          <title>Flovent 500 in Adolescent/Adult Group</title>
          <description>Flovent 500 in participants 12 years and older</description>
        </group>
        <group group_id="E6">
          <title>Advair 250/50 in Adolescent/Adult Group</title>
          <description>Advair 250/50 in participants 12 years and older</description>
        </group>
        <group group_id="E7">
          <title>Flovent 250 in Adolescent/Adult Group</title>
          <description>Flovent 250 in participants 12 years and older</description>
        </group>
        <group group_id="E8">
          <title>Advair 100/50 in Adolescent/Adult Group</title>
          <description>Advair 100/50 in participants 12 years and older</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="294"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="294"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="294"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Acute Peptic Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Chest Pain Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsions Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Syncope and Collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Adverse Food Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Anaphylactic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Closed Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar Spinal Cord Compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant Neoplasm Brain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Malignant Neoplasm Thyroid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Post-Op Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Drug Withdrawal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Intermittent Explosive Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="280"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="280"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="294"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="294"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="294"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="20" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E2" events="23" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E3" events="24" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E4" events="21" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="294"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="280"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Nasopharyngitis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" events="36" subjects_affected="18" subjects_at_risk="280"/>
                <counts group_id="E3" events="33" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E4" events="39" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E5" events="33" subjects_affected="24" subjects_at_risk="294"/>
                <counts group_id="E6" events="46" subjects_affected="27" subjects_at_risk="294"/>
                <counts group_id="E7" events="40" subjects_affected="20" subjects_at_risk="294"/>
                <counts group_id="E8" events="42" subjects_affected="22" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Acute Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="280"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E4" events="20" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E5" events="19" subjects_affected="11" subjects_at_risk="294"/>
                <counts group_id="E6" events="15" subjects_affected="11" subjects_at_risk="294"/>
                <counts group_id="E7" events="24" subjects_affected="16" subjects_at_risk="294"/>
                <counts group_id="E8" events="20" subjects_affected="13" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" events="41" subjects_affected="23" subjects_at_risk="280"/>
                <counts group_id="E2" events="47" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E3" events="54" subjects_affected="40" subjects_at_risk="280"/>
                <counts group_id="E4" events="31" subjects_affected="18" subjects_at_risk="280"/>
                <counts group_id="E5" events="20" subjects_affected="18" subjects_at_risk="294"/>
                <counts group_id="E6" events="20" subjects_affected="17" subjects_at_risk="294"/>
                <counts group_id="E7" events="22" subjects_affected="17" subjects_at_risk="294"/>
                <counts group_id="E8" events="23" subjects_affected="18" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Mauger</name_or_title>
      <organization>Penn State University</organization>
      <phone>717-531-7178</phone>
      <email>dmauger@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

